Cargando…

Advancing Cancer Research: Insights and Innovations in Pathogenesis and Targeted Therapies

Detalles Bibliográficos
Autores principales:	Wu, Yong, Vadgama, Jaydutt V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051869/ https://www.ncbi.nlm.nih.gov/pubmed/36983557 http://dx.doi.org/10.3390/jpm13030375

Ejemplares similares

CCL2/CCR2 signaling in cancer pathogenesis
por: Hao, Qiongyu, et al.
Publicado: (2020)

Potential Therapies Targeting the Metabolic Reprogramming of Diabetes-Associated Breast Cancer
por: Shum, Hang Chee Erin, et al.
Publicado: (2023)

Celecoxib in breast cancer prevention and therapy
por: Li, Jieqing, et al.
Publicado: (2018)

AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
por: Cao, Wei, et al.
Publicado: (2019)

From Interaction to Intervention: How Mesenchymal Stem Cells Affect and Target Triple-Negative Breast Cancer
por: Wu, Yong, et al.
Publicado: (2023)

Challenges in understanding Sjögren's syndrome - improved insights into the pathogenesis generate hope for innovative therapies?
por: Dörner, Thomas
Publicado: (2011)

Basal-like breast cancer with low TGFβ and high TNFα pathway activity is rich in activated memory CD4 T cells and has a good prognosis
por: Liu, Dingxie, et al.
Publicado: (2021)

Epithelial-Mesenchymal Transition and Breast Cancer
por: Wu, Yanyuan, et al.
Publicado: (2016)

Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer
por: Deng, Wenhong, et al.
Publicado: (2021)

Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase
por: Chung, Seyung S., et al.
Publicado: (2016)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits
por: CHUNG, SEYUNG S., et al.
Publicado: (2013)

Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies
por: Hao, Qiongyu, et al.
Publicado: (2022)

Estrogen receptor-beta is a potential target for triple negative breast cancer treatment
por: Austin, David, et al.
Publicado: (2018)

GROα overexpression drives cell migration and invasion in triple negative breast cancer cells
por: Bhat, Kruttika, et al.
Publicado: (2017)

Constitutive Activation of STAT3 Signaling Regulates hTERT and Promotes Stem Cell-Like Traits in Human Breast Cancer Cells
por: Chung, Seyung S., et al.
Publicado: (2013)

Innovations in Personalized and Targeted Therapies for Breast Cancer
por: Harris, Eleanor E. R., et al.
Publicado: (2018)

Translational and Comparative Research on Innovative Anti-Cancer Therapies
por: Queiroga, Felisbina, et al.
Publicado: (2023)

Diaporine Potentiates the Anticancer Effects of Oxaliplatin and Doxorubicin on Liver Cancer Cells
por: Tian, Shiliu, et al.
Publicado: (2022)

Genetic variants in African-American and Hispanic patients with breast cancer
por: Dutta, Pranabananda, et al.
Publicado: (2022)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

Lactate, a Neglected Factor for Diabetes and Cancer Interaction
por: Wu, Yong, et al.
Publicado: (2016)

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
por: Dutta, Pranabananda, et al.
Publicado: (2018)

Pathogenesis and Targeted Therapy of Epilepsy
por: N’Gouemo, Prosper
Publicado: (2022)

Tumor-Derived Exosomes in Tumor-Induced Immune Suppression
por: Hao, Qiongyu, et al.
Publicado: (2022)

Harnessing Oxidative Stress as an Innovative Target for Cancer Therapy
por: Postovit, Lynne, et al.
Publicado: (2018)

Innovative research and technological advancements: Oars of the boat of progress
por: Bajwa, Sukhminder Jit Singh, et al.
Publicado: (2023)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
por: Wu, Yanyuan, et al.
Publicado: (2020)

Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer
por: Dutta, Pranabananda, et al.
Publicado: (2020)

Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women
por: Wu, Yanyuan, et al.
Publicado: (2017)

Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets
por: Nava, Miguel, et al.
Publicado: (2019)

Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN
por: Wu, Yanyuan, et al.
Publicado: (2013)

The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
por: Elshimali, Yahya I., et al.
Publicado: (2013)

Advancing healthcare simulation research: innovations in theory, methodology, and method
por: Eppich, Walter, et al.
Publicado: (2022)

Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
por: Wu, Yanyuan, et al.
Publicado: (2010)

Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression
por: Sterling, Colin, et al.
Publicado: (2022)

Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women
por: Wu, Yanyuan, et al.
Publicado: (2022)

New Insights into Diabetic Kidney Disease: The Potential Pathogenesis and Therapeutic Targets
por: Liu, Wei Jing, et al.
Publicado: (2017)

Special Issue: New Insights into the Pathogenesis and Therapies of IgA Nephropathy
por: Suzuki, Hitoshi, et al.
Publicado: (2022)

New Insights into Bacterial Pathogenesis
por: Biondo, Carmelo
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sjqt0voapeimr859br4fv8v9en